Rémy Morgentin

439 total citations
14 papers, 298 citations indexed

About

Rémy Morgentin is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Rémy Morgentin has authored 14 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Organic Chemistry and 3 papers in Oncology. Recurrent topics in Rémy Morgentin's work include Chemical Synthesis and Analysis (6 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). Rémy Morgentin is often cited by papers focused on Chemical Synthesis and Analysis (6 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). Rémy Morgentin collaborates with scholars based in United Kingdom, France and Denmark. Rémy Morgentin's co-authors include Adam Nelson, Tuomo Kalliokoski, Patrick A. Plé, Didier Roche, Fabrizio Giordanetto, Jorg C. J. Benningshof, Stephen P. Marsden, Daniel Hamza, Christine Lambert‐van der Brempt and Mads H. Clausen and has published in prestigious journals such as Journal of Medicinal Chemistry, Tetrahedron and RSC Advances.

In The Last Decade

Rémy Morgentin

14 papers receiving 284 citations

Peers

Countries citing papers authored by Rémy Morgentin

Since Specialization

Citations

This map shows the geographic impact of Rémy Morgentin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rémy Morgentin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rémy Morgentin more than expected).

Fields of papers citing papers by Rémy Morgentin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rémy Morgentin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rémy Morgentin. The network helps show where Rémy Morgentin may publish in the future.

Co-authorship network of co-authors of Rémy Morgentin

This figure shows the co-authorship network connecting the top 25 collaborators of Rémy Morgentin. A scholar is included among the top collaborators of Rémy Morgentin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rémy Morgentin. Rémy Morgentin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Realisation of small molecule libraries based on frameworks distantly related to natural products 2018 ·Organic & Biomolecular Chemistry ·A. Aimon, George Karageorgis, (unknown), Mark Dow, (unknown), (unknown), (unknown), Rémy Morgentin, (unknown), (unknown), Tuomo Kalliokoski, Andrew J. Eatherton, Daniel J. Foley, Stephen P. Marsden, Adam Nelson	14
2	Translation of innovative chemistry into screening libraries: an exemplar partnership from the European Lead Factory 2018 ·Drug Discovery Today ·Rémy Morgentin, Mark Dow, A. Aimon, George Karageorgis, Tuomo Kalliokoski, Didier Roche, Stephen P. Marsden, Adam Nelson	11
3	Generation of a Heteropolycyclic and sp³‐Rich Scaffold for Library Synthesis from a Highly Diastereoselective Petasis/Diels–Alder and ROM–RCM Reaction Sequence 2018 ·European Journal of Organic Chemistry ·(unknown), (unknown), (unknown), Geanna K. Min, Yohan Macé, (unknown), (unknown), (unknown), (unknown), Rémy Morgentin, Thomas E. Nielsen, Mads H. Clausen	7
4	Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours 2017 ·Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Sabina Cosulich, Sébastien L. Degorce, Rebecca Ellston, Martina Fitzek, Stephen Green, Urs J. Hancox, Christine Lambert‐van der Brempt, (unknown), (unknown), Rémy Morgentin, Patrick A. Plé, Lara Ward, Nicolas Warin	3
5	Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours 2016 ·Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Sabina Cosulich, Sébastien L. Degorce, Martina Fitzek, Stephen Green, Urs J. Hancox, Christine Lambert‐van der Brempt, (unknown), (unknown), Rémy Morgentin, (unknown), Patrick A. Plé, (unknown), Lara Ward, Nicolas Warin	6
6	Tandem Mannich/Diels–Alder reactions for the synthesis of indole compound libraries 2016 ·RSC Advances ·Peng Wu, Michael Petersen, (unknown), (unknown), (unknown), (unknown), Rémy Morgentin, Thomas E. Nielsen, Mads H. Clausen	12
7	Synthesis of sp³-rich scaffolds for molecular libraries through complexity-generating cascade reactions 2016 ·Organic & Biomolecular Chemistry ·(unknown), (unknown), (unknown), Rémy Morgentin, Didier Roche, Mads H. Clausen, Thomas E. Nielsen	28
8	Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective 2015 ·Drug Discovery Today ·Anna Karawajczyk, Fabrizio Giordanetto, Jorg C. J. Benningshof, Daniel Hamza, Tuomo Kalliokoski, Kees Pouwer, Rémy Morgentin, Adam Nelson, Gerhard Müller, (unknown), Dimitrios Tzalis	70
9	Exploitation of the Ugi–Joullié Reaction in the Synthesis of Libraries of Drug-Like Bicyclic Hydantoins 2015 ·Synthesis ·Adam Nelson, James D. Firth, Rong Zhang, Rémy Morgentin, (unknown), Tuomo Kalliokoski, Stuart L. Warriner, Richard Foster, Stephen P. Marsden	15
10	Design, synthesis and decoration of molecular scaffolds for exploitation in the production of alkaloid-like libraries 2014 ·Bioorganic & Medicinal Chemistry ·(unknown), A. Aimon, Mark Dow, Nicolas Fleury‐Brégeot, (unknown), Rémy Morgentin, Didier Roche, Tuomo Kalliokoski, Richard Foster, Stephen P. Marsden, Adam Nelson	25
11	Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours 2014 ·Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Sabina Cosulich, Sébastien L. Degorce, Martina Fitzek, Fabrizio Giordanetto, Stephen Green, Tord Inghardt, Laurent Hennequin, Urs J. Hancox, Christine Lambert‐van der Brempt, Rémy Morgentin, (unknown), Patrick A. Plé, (unknown), Lara Ward	17
12	Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers 2014 ·Journal of Medicinal Chemistry ·Bernard Barlaam, Sabina Cosulich, Sébastien L. Degorce, Martina Fitzek, Stephen Green, Urs J. Hancox, Christine Lambert‐van der Brempt, (unknown), (unknown), Rémy Morgentin, (unknown), (unknown), Patrick A. Plé, (unknown), (unknown), Mike Walker, Lara Ward, Nicolas Warin	66
13	Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases 2012 ·Bioorganic & Medicinal Chemistry Letters ·Patrick A. Plé, Frédéric Jung, Sue Ashton, Laurent Hennequin, (unknown), Christine Lambert‐van der Brempt, Rémy Morgentin, Georges Pasquet, Sian Taylor	7
14	An efficient large-scale synthesis of alkyl 5-hydroxy-pyridin- and pyrimidin-2-yl acetate 2008 ·Tetrahedron ·Rémy Morgentin, Frédéric Jung, (unknown), (unknown), (unknown), Patrick A. Plé, Georges Pasquet, Fabrice G. Renaud	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact